Tenet Healthcare Director Sold Company Shares
Director Nadja West offloaded a portion of her equity stake in the company on September 2, 2026.
Updated on Sept. 20, 2026 in Healthcare
Live Poll
Do you trust executive stock sales as a signal of a company's future performance?
Tenet Healthcare director Nadja West sold 1,152 shares of common stock on September 2, 2026. This open-market transaction generated approximately $298,138 in total proceeds for the director.
Why it matters
The sale represents 5% of the director's direct common stock holdings, leaving her with a remaining stake of 23,653 shares. The company has seen significant growth, recording a 39% total return over the one-year period preceding the transaction.
The stock sale was executed at a weighted average price of $258.80 per share, which contributes to the company's $21.8 billion in trailing twelve-month revenue. Tenet Healthcare currently maintains a net income of $2.2 billion.
The players
Nadja West
Nadja West is a member of the Board of Directors at Tenet Healthcare.
Tenet Healthcare
Tenet Healthcare is a diversified healthcare services company that operates 77,000 employees.
The details
The divestment occurred following a period of strong performance for the healthcare firm, which employs 77,000 individuals across the United States. Following the sale, analysts remain optimistic about the firm's trajectory, with 83% of coverage analysts rating the stock as a buy and a median one-year price target of $284.
Timeline
Nadja West sold 1,152 shares of Tenet Healthcare stock on September 2, 2026.
Market Landscape
This transaction follows the disclosure protocols mandated by the Securities and Exchange Commission for corporate leadership. The sale of equity by a director is a routine event that complies with the regulatory transparency requirements set for public companies.
The director's sale of shares has no direct impact on the service costs or availability of care for Tenet Healthcare patients. Shareholders and investors continue to monitor analyst buy ratings as the company maintains its current revenue trajectory.
The takeaway
The transaction reflects a minor adjustment to an individual director's portfolio rather than a shift in company fundamentals. Investors typically monitor these filings for signals on internal sentiment, though the current analyst consensus remains largely positive.
Further reading
For more on industry performance, see Healthcare.
Source note: This article includes information reported by The Motley Fool.
Live Poll
Do you trust executive stock sales as a signal of a company's future performance?
